Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 605 of 5804
-
Can a new drug ST316 shrink Hard-to-Treat tumors?
Disease control OngoingThis is an open-label, two-part, phase 1-2 study designed to determine the safety, tolerability, PK, pharmacodynamics (PD), and proof-of-concept efficacy of ST316 administered IV in subjects with selected advanced solid tumors likely to harbor abnormalities of the WNT/β-catenin s…
Phase: PHASE1 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Sleep hormone may shield kidneys from antibiotic harm
Prevention Recruiting nowThis study will evaluate the safety and effectiveness of melatonin for the prevention of antibiotic associated acute kidney injury in hospitalized patients.
Phase: PHASE3 • Sponsor: Rutgers, The State University of New Jersey • Aim: Prevention
Last updated Jun 27, 2026 08:04 UTC
-
Can data and doulas close the racial gap in maternal care?
Disease control Recruiting nowThis project-also known as "Accountability for Care through Undoing Racism \& Equity for Moms" or ACURE4Moms-aims to reduce Black-White maternal health disparities using multi-level interventions designed to decrease bias in prenatal care, improve care coordination, and increase …
Phase: NA • Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New radiation bead treatment targets Hard-to-Treat pancreatic tumors
Disease control Recruiting nowPancreatic ductal adenocarcinoma is a highly lethal cancer, and approximately 40% of patients present with non-metastatic locally advanced pancreatic cancer (LAPC) that is not suitable for surgical resection. To improve outcomes in this patient group, local ablative treatments ar…
Phase: PHASE1, PHASE2 • Sponsor: M.R. Meijerink • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo targets tough leukemia in early trial
Disease control OngoingThis is a national, open-label, single-arm, multicenter phase II trial evaluating the safety and efficacy of adding gilteritinib, a new FLT3 inhibitor to the AGORA platform, consisting of the combination of an intermediate dose of cytarabine and a divided dose of GO in adult pati…
Phase: PHASE2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Twice-Yearly shot could halt early puberty in kids
Disease control CompletedThe study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with central (gonadotropin-dependent) precocious puberty, when administered as two injections six months apart.
Phase: PHASE3 • Sponsor: Foresee Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Immunotherapy duo shows promise against advanced oral cancer
Disease control OngoingTo learn if treatment with tiragolumab and atezolizumab before and after standard of care surgery and chemoradiation (radiation therapy with or without cisplatin/carboplatin) can help to control OCSCC that is PD-L1 CPS positive.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for brain metastases? drug duo targets advanced cancers
Disease control Recruiting nowTo learn if the combination of niraparib and dostarlimab can help to control advanced cancer that has spread to the brain.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug could unlock kidney transplants for sensitized kids
Disease control Recruiting nowThe goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD). The main questions it aims to answer are: * Does imlifidase treatment result in crossmatch conv…
Phase: PHASE2 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Stroke drug may work hours later than thought
Disease control CompletedThis study is designed to evaluate the efficacy of IV rhTNK-tPA between 4.5 to 24 hours from symptom onset in patients presenting with a non-large vessel occlusion ischemic stroke.
Phase: PHASE4 • Sponsor: Xuanwu Hospital, Beijing • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New antibody-drug combo targets tough cervical cancers in early trial
Disease control Recruiting nowThis is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Cheaper MS drug could match costly standard in new trial
Disease control Recruiting nowThe goal of this randomized clinical trial is to compare relapse remitting multiple sclerosis (RRMS) patients treated by ocrelizumab or by rituximab followed for 2 years. The main question it aims to answer is : • to demonstrate the non-inferiority of rituximab versus ocrelizumab…
Phase: PHASE3 • Sponsor: Rennes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Stroke recovery goes home: nerve-stim therapy tested in living rooms
Disease control OngoingThis is a single-arm post-market study of up to 150 participants, using up to 50 mobile therapists to conduct up to 36-hours at-home therapy. The study will assess at-home therapy implementation instead of an in-clinic therapy implementation for patients who are commercially impl…
Sponsor: MicroTransponder Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo offers hope for tough lung cancer
Disease control Recruiting nowDZD9008 in combination with AZD4205 for the treatment of patients with advanced NSCLC with EGFR mutations who have progressed after standard treatment. The purpose of this study is to assess the safety and efficacy of this combination therapy.
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Can longer pyrotinib use keep breast cancer at bay?
Disease control Recruiting nowThis is a prospective, randomised, controlled, multicentre study to compare the efficacy and safety between continuous or intermittent extension of adjuvant pyrotinib in invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Phase: PHASE3 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can churches help prevent suicide in black communities? new study tests a Multi-Generational program
Prevention Recruiting nowHAVEN=CONNECT is a comprehensive depression and suicide prevention intervention that is designed to be integrated into predominantly Black churches, a strategically ideal location for mental health intervention for Black youth. HAVEN=CONNECT has three components: (1) Church Commu…
Phase: NA • Sponsor: George Washington University • Aim: Prevention
Last updated Jul 22, 2026 00:00 UTC
-
Breath test could revolutionize lung cancer screening
Diagnosis Recruiting nowThe trial will evaluate if the newly identified biomarkers of lung cancer in exhaled breath condensate are as a diagnostic tool comparable to the low-dose computer tomography (LDCT) implemented in lung cancer screening recently. Due to the possibility to collect breath condensate…
Phase: NA • Sponsor: The Institute of Molecular and Translational Medicine, Czech Republic • Aim: Diagnosis
Last updated Jun 27, 2026 09:05 UTC
-
New gel fusion technique aims to speed nerve repair after traumatic arm injuries
Disease control Recruiting nowThe overall objective of this study is to determine the safety of PEG fusion when used with primary repair or reconstruction in patients with an acute upper extremity peripheral nerve injury. PEG is safe and effective for extending the half-life of circulating pharmaceutical prod…
Phase: PHASE2 • Sponsor: Major Extremity Trauma Research Consortium • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can a simple program slash postpartum depression for every mom?
Prevention Recruiting nowThe Reach Out, Stand Strong, Essentials for New Mothers (ROSE) program is an evidence-based intervention that prevents half of cases of postpartum depression and was one of two interventions recommended by the US Preventive Services Task Force in 2019. All effectiveness trials of…
Phase: NA • Sponsor: Michigan State University • Aim: Prevention
Last updated Jun 27, 2026 12:34 UTC
-
Virtual reality takes on alcohol addiction: a new weapon against relapse?
Disease control CompletedThis study aims to compare the efficacy of virtual reality exposure therapy (VRET) with treatment-as-usual (TAU) for alleviating psychological dependence on alcohol and preventing relapse. It also assesses the changes of EEG in patients with alcohol use disorder after completion …
Phase: NA • Sponsor: Universiti Sains Malaysia • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC